Transdermal apomorphine permeation from microemulsions: A new treatment in Parkinson's disease

@article{Priano2004TransdermalAP,
  title={Transdermal apomorphine permeation from microemulsions: A new treatment in Parkinson's disease},
  author={Lorenzo Priano and Gianni Albani and Andrea Brioschi and Sara Calderoni and Leonardo Lopiano and Mario Giorgio Rizzone and Roberta Cavalli and Maria Rosa Gasco and Francesco Scaglione and Franco Fraschini and Bruno Bergamasco and Alessandro Mauro},
  journal={Movement Disorders},
  year={2004},
  volume={19}
}
We studied absorption, efficacy, and tolerability in Parkinson's disease (PD) of a new preparation of apomorphine included in a microemulsion and administered by transdermal route (Apo‐MTD). Twenty‐one PD patients were treated with levodopa plus oral dopamine‐agonists (T0), with levodopa alone (T1), finally with levodopa plus Apo‐MTD (T2). Apo‐MTD provided therapeutic plasma levels for many hours, improved Unified Parkinson's Disease Rating Scale III scores, and reduced total duration of off… 
Transdermal drug delivery in Parkinson’s disease
TLDR
The recent emergence of rotigotine as an effective transdermal therapy provides hope and encouragement that additional advances may also be forthcoming and that the ability to effectively treat this devastating disease will continue to grow.
Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease
TLDR
Transdermally delivered rotigotine is a clinically innovative and useful addition to the dopamine‐receptor agonist class and can improve early morning and nocturnal symptoms of Parkinson's disease.
Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease
  • F. Grandas
  • Medicine
    Expert review of neurotherapeutics
  • 2013
TLDR
The therapeutic effect of continuous apomorphine infusion is reviewed, practical recommendations on its use are provided and the patient's quality of life is improved.
Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy.
TLDR
The study confirmed the feasibility and potential of transdermal delivery of RSM via simple topical application of R SM-MEG, and this approach could be an alternative therapeutic intervention for the treatment of Parkinson's disease.
Transdermal Treatment Options for Neurological Disorders
TLDR
Although most transdermal delivery systems treatments cannot be considered as first-line therapy at present, some of them provide clear advantages compared with other routes of administration and may become the preferred treatment in selected patients.
Continuous levodopa for advanced Parkinson’s disease
  • C. Lundqvist
  • Medicine
    Neuropsychiatric disease and treatment
  • 2007
TLDR
The challenges to treatment of Parkinson’s disease in these phases are described as well as the various treatment alternatives available, mainly on the clinical studies of continuous levodopa infusion therapies, especially enteral administration oflevodopa/carbidopa gel.
Application of Microemulsions in Dermal and Transdermal Drug Delivery
TLDR
This review discusses some of the applications of microemulsions specifically for topical and transdermal applications and the issues which warrant further investigation by researchers in order to realize the full potential of the technology.
Iontophoretic delivery of selected antiparkinsonian agents in vitro
TLDR
This thesis focuses on the management of Parkinson’s disease through the treatment of Dopamine agonists and the challenges in treatment of PD.
Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
TLDR
This review discusses and summarizes the most recent developments in this field with a focus on non-oral dopaminergic strategies in development or to be licensed for management of Parkinson’s disease.
Apomorphine therapy in Parkinson's disease: a review
TLDR
The history, pharmacology, efficacy, safety, and proper administration of apomorphine for treating ‘off’ states in Parkinson's disease are discussed, with a focus on intermittent subcutaneous administration.
...
1
2
3
4
...

References

SHOWING 1-10 OF 32 REFERENCES
Absorption of apomorphine by various routes in parkinsonism
TLDR
It is concluded that apomorphine is effectively absorbed by the sublingual route and used as an adjunct with levodopa in parkinsonism.
Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
TLDR
The results indicated that SL apomorphine can reduce severe off periods in parkinsonian patients when used chronically, and its long-term use is limited by a severe side effect (stomatitis).
Apomorphine: An underutilized therapy for Parkinson's disease
  • W. Poewe, G. Wenning
  • Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 2000
TLDR
There is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa‐induced dyskinesias and this approach seems to deserve more widespread clinical use.
lontophoretic Delivery of Apomorphine II: An In Vivo Study in Patients with Parkinson's Disease
TLDR
The results show that current-dependent delivery of apomorphine is possible in vivo at acceptable levels of skin irritation and excellent correlation was found between the calculatedin vivo transport rates and the rates that were previously obtained in vitro.
Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease.
TLDR
It is felt that the good short-term efficacy and tolerability demonstrated in this study warrant further study of this new preparation, as there are several potential advantages of sublingual administration compared with traditional APO preparations.
Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up
TLDR
Subcutaneous apomorphine is a highly effective treatment which can substantially improve the symptomatology in patients with advanced stage Parkinson’s disease over a prolonged period of time.
Pharmacokinetics of apomorphine in Parkinson's disease.
  • S. Gancher
  • Medicine
    Journal of neural transmission. Supplementum
  • 1995
TLDR
Apomorphine rapidly equilibrates between plasma and brain, and like levodopa, the response tends to be largely "all or none"; larger doses produce a longer duration of effect within a 30-90 minute range.
Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily
A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease
TLDR
The short‐term benefit and tolerability demonstrated in this study warrant further study of this new APO preparation, which was tested in 10 patients with advanced Parkinson's disease complicated by motor fluctuations.
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: A study of five different suppositories
TLDR
Results show that rectal administration of apomorphine may present an alternative to subcutaneous administration in patients with idiopathic Parkinson's disease and the sustained‐release properties of the Witepsol‐H15 suppository are especially of interest in the treatment of on‐off fluctuations in PD.
...
1
2
3
4
...